BA (Hons) · MSc · DClinPsy (USA) · GMBPsS
Founder of Cosmos Healthcare and architect of the QPAN® precision neuromodulation protocol system. A recognised authority in QEEG-guided neuromodulation, with over twenty-seven years of clinical experience in neurodevelopmental assessment, treatment-resistant conditions, and neurorehabilitation. Published author and regular speaker at international conferences, and Expert Court Witness for Civil Law.
Dr Alptekin Aydin graduated with First-Class Honours in Psychology from Istanbul University before completing a postgraduate Master's degree at the Institute of Psychiatry, Psychology & Neuroscience (IoPPN), King's College London, where he trained in Neurological and Pharmacological Substance Addiction. He subsequently obtained his International Clinical TMS Certification from Maastricht University, accredited by the European Accreditation Council for Continuing Medical Education (EACCME).
His doctoral and subsequent research has focused on neurodevelopmental conditions, quantitative EEG (QEEG), and personalised neuromodulation. His current peer-reviewed work includes research examining QEEG-guided rTMS and neurophysiological change in autism spectrum disorder.
In 2018, Dr Aydin developed QPAN®, a structured framework integrating QEEG-derived information with NeuroMap® analysis and clinician-led neuromodulation planning. Since its development, QPAN® has been used within clinical and research workflows involving neurodevelopmental presentations. Its role is to support structured assessment, individualised clinical review and longitudinal monitoring. Individual outcomes vary, and no specific clinical improvement is guaranteed.
"Accurate diagnosis is not merely the beginning of treatment; it is often the treatment itself. When patients truly understand what is happening in their brain, they become active participants in their own recovery."
— Dr Alptekin AydinDr Aydin holds additional certifications in QEEG Reporting and Advanced EEG Interpretation (Florida, USA), and Expert Witness for Civil Law (Cardiff School of Law and Politics, Bond Solon).
Dr Aydin accepts referrals for assessment and treatment across a range of complex neurological and psychological conditions.
Asperger's Syndrome · Giftedness · Speech & Language Disorders · Voice Disorders · Chewing & Swallowing Disorders · Dyslexia · Dysgraphia · Dyscalculia · Developmental Delay · Neurological Pain · Stroke Rehabilitation · Anxiety Disorders · Panic Attacks · Bipolar Disorders · Post-Traumatic Stress · Problematic Gambling · Cannabis Misuse · Cocaine Addiction · Alcohol Addiction · Smoking Cessation
Comprehensive neuropsychological services from initial consultation through to advanced neuromodulation therapy.
Quantitative EEG provides additional objective information about electrical brain activity and may support longitudinal comparison where clinically appropriate. QEEG is interpreted alongside clinical assessment; it does not independently establish a diagnosis, treatment target, treatment effect or expected response.
Transcranial Magnetic Stimulation (TMS) is a non-invasive neuromodulation technique. NICE guidance supports rTMS for depression with normal arrangements for clinical governance and audit, while individual response remains variable. For OCD, NICE states that efficacy evidence is currently inadequate in quantity and quality and recommends TMS only in the context of research.
Transcranial Pulse Stimulation (TPS) is a non-invasive neuromodulation modality under active investigation in neurodegenerative and other neurological presentations. Any use is considered individually, with discussion of the available evidence, uncertainties, alternatives and clinical suitability.
tDCS is a non-invasive neuromodulation technique. NICE guidance for depression reports some evidence of efficacy but also important uncertainties and recommends special arrangements for clinical governance, consent and audit or research. Evidence and regulatory status vary by indication.
Holistic support therapies integrated within our comprehensive treatment programmes. These complementary approaches work alongside evidence-based neuromodulation and psychological therapy.
Structured programmes to improve cognitive function, attention, memory, and executive skills. Evidence-based approaches tailored to individual neuropsychological profiles.
TMS, rTMS and tDCS are non-invasive neuromodulation techniques capable of modulating neural activity in targeted regions. Their clinical relevance, suitability and supporting evidence differ by condition and protocol, and individual outcomes cannot be assumed.
Comprehensive neuropsychological evaluation to understand cognitive strengths and challenges, informing personalised treatment approaches and tracking progress throughout intervention.
Various talk therapies including Cognitive Behavioural Therapy (CBT), psychodynamic therapy, and other evidence-based psychological interventions tailored to individual needs.
Lifestyle changes, nutrition guidance, exercise programmes, and other structured health interventions that support overall wellbeing and complement medical treatments.
Comprehensive treatment programmes combining QEEG-guided neuromodulation with psychological therapies for specific clinical presentations.
Our neurodevelopmental pathway combines specialist assessment, standardised measures and, where clinically appropriate, QEEG-informed neurophysiological evaluation. Neuromodulation may be considered only after individual suitability review. In autism, neuromodulation remains an evolving research area and no specific functional or clinical outcome can be guaranteed.
NICE-approved TMS therapy combined with psychological support for treatment-resistant depression, anxiety, and OCD. Personalised protocols based on individual neurological profiles.
Advanced TPS and multimodal neuromodulation for Alzheimer's disease and Parkinson's disease. Targeting deeper brain structures to support cognitive function and motor symptoms.
Intensive treatment combining TMS neuromodulation with evidence-based psychological therapy. Extensive clinical experience with thousands of patients. Addresses cannabis, alcohol, cocaine, gambling, and behavioural addictions.
Each patient receives a structured, evidence-based approach tailored to their specific presentation and clinical needs.
Every treatment programme begins with comprehensive assessment, including detailed clinical history, standardised psychometric testing, and where indicated, QEEG brain mapping.
Treatment recommendations are grounded in the best available scientific evidence. Dr Aydin maintains active engagement with the research literature.
Effective treatment requires active patient engagement. Dr Aydin places significant emphasis on ensuring patients understand their condition.
Treatment protocols are regularly reviewed and adjusted based on patient progress and QEEG findings.
QEEG-Guided Personalised NeuroMap®-Based Neuromodulation — an innovative approach combining advanced brain mapping, our proprietary NeuroMap® technology, and targeted neuromodulation for neurodevelopmental conditions. Developed and published by Dr Alptekin Aydin.
QEEG provides quantitative information about recorded electrical brain activity. Within QPAN®, eligible QEEG-derived measures can be organised alongside clinical information to support individualised review and longitudinal comparison. QEEG is not used as a stand-alone diagnostic test for autism.
NeuroMap® organises QEEG-derived measures and predefined analytical outputs to support structured clinician review and longitudinal comparison. Its outputs constitute decision-support information and do not independently establish diagnosis, treatment efficacy, optimal treatment or a guaranteed outcome.
Non-invasive tDCS and TMS stimulate targeted brain regions to support cognitive function and behavioural outcomes through gentle, painless sessions.
Beyond neuromodulation, QPAN® combines speech therapy, behavioural interventions, and tailored education programmes for comprehensive care.
A trailblazer in remote autism treatment, Dr Aydin was among the first to implement worldwide home-based neuromodulation therapies guided by QEEG.
Participating in remote QPAN® sessions through our secure app-based system, managing treatment in the comfort of their homes.
CE-marked tDCS headsets enabling safe, clinically supervised home-based neuromodulation following individualised QEEG-guided protocols.
A private support community of families worldwide who have completed or are continuing treatment, sharing their experiences with the QPAN® model.
Dr Aydin organised and led a seminar and workshop at Oxford University focusing on the assessment and treatment of children with autism, ADHD, and learning difficulties.
The event brought together world-class researchers, neurobiologists, and QEEG specialists to discuss the latest scientific developments in functional brain assessment, precision neuromodulation, and integrated behavioural therapy approaches.
Dr Aydin regularly presents at international conferences on neurodevelopmental conditions and therapeutic neuromodulation.
A Journey of Hope: Helping Thousands of Autistic Children Through QPAN®
Drawing on over 27 years of clinical experience and the treatment of thousands of children with autism spectrum conditions, Dr Aydin shares his pioneering approach to neurodevelopmental care in this comprehensive guide for families and professionals.
The book explores the science behind QEEG-guided neuromodulation, the development of the QPAN® protocol system, and offers hope and practical guidance for families navigating the autism journey.
Dr Aydin's peer-reviewed research focuses on QEEG-guided neuromodulation for autism spectrum disorder, contributing to evidence-based personalised treatment approaches.
This single-case report examines how repetitive transcranial magnetic stimulation (rTMS) affects multiscale neurophysiological biomarkers in ASD, using advanced EEG analytic methods including spectral parameterization and long-range temporal correlation assessment.
Read More →A within-cohort reanalysis examining QEEG-guided repetitive transcranial magnetic stimulation outcomes in pediatric ASD, contextualized alongside emerging evidence for home-based tDCS interventions targeting the dorsolateral prefrontal cortex.
Read More →Dr Aydin provides expert neuropsychological opinion for courts, tribunals, and legal proceedings, fully compliant with the Civil Procedure Rules (CPR Part 35).
Dr Aydin holds the Cardiff University Bond Solon (CUBS) Civil Expert Witness Certificate — widely recognised as the "gold standard" for expert witnesses operating within the legal framework of England and Wales. This joint accreditation from Cardiff University School of Law and Politics and Bond Solon rigorously validates his ability to provide competent, impartial expert evidence.
All medico-legal reports are prepared in strict compliance with the Civil Procedure Rules. Dr Aydin provides detailed, objective, and scientifically grounded reports based on QEEG functional brain mapping and comprehensive neuropsychological assessment for:
The CUBS certification demonstrates proven competence in excellence in report writing, full understanding of civil law and an expert's overriding duty to the court, and effective courtroom skills including cross-examination. Dr Aydin provides robust, objective evidence that withstands legal scrutiny.
"Following years of unsuccessful treatment for depression, the TMS programme designed by Dr Aydin has been transformative. His thorough approach to assessment meant the treatment was precisely targeted. The improvement has been remarkable."
33 London Road, Redwood House
Enfield EN2 6DR
Monday – Saturday
10am – 6pm
To arrange a consultation with Dr Aydin, please contact the practice by telephone or email. Referrals are accepted from GPs, consultants, and self-referring patients.
This is not an emergency service. For urgent mental health support, please contact NHS 111, your GP, or emergency services.